Recruiting NA Hearing Loss, Sensorineural

New treatment option for Hearing Loss, Sensorineural

Official title Clinical Utility of Residual Hearing in the Cochlear Implant Ear

ClinicalTrials.gov ID: NCT04707885

What this study is testing

What it's testing
The current study is a randomized multi-center clinical trial that investigates the role an intraoperative hearing monitoring system (electrocochleography) has on helping to save residual hearing in patients undergoing cochlear implantation (CI).
  • Which group you join is decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 79

You may be able to join if

  • Provision of signed and dated informed consent form.
  • Adults, males and females, ages 18 -79 who have a bilateral sensorineural hearing loss with postlingual onset.
  • Minimum of 30 days experience with appropriately fit binaural amplification (standardized National Acoustic Laboratories (NAL) fitting method)...
  • Limited benefit from conventional amplification in the best aided condition as defined by test scores of:
  • The ear to implanted: Consonant-nucleus-consonant (CNC) words ≤ 60% or AzBio sentences (+10, +5 dB SNR ≤ 60% correct)

You likely can't join if

  • Previous cochlear implantation.
  • Prelingual onset of hearing loss.
  • Abnormal inner ear anatomy on CT imaging.
  • Auditory neuropathy spectrum disorder.
  • Retrocochlear pathology such as a vestibular schwannoma or stroke.
  • Unwillingness or inability to comply with all investigational requirements including the randomization process.
See the full eligibility criteria
Who can join
  • Provision of signed and dated informed consent form.
  • Adults, males and females, ages 18 -79 who have a bilateral sensorineural hearing loss with postlingual onset.
  • Minimum of 30 days experience with appropriately fit binaural amplification (standardized National Acoustic Laboratories (NAL) fitting method) verified with real ear measurements within 5 dB SPL of targets.
  • Limited benefit from conventional amplification in the best aided condition as defined by test scores of:
  • The ear to implanted: Consonant-nucleus-consonant (CNC) words ≤ 60% or AzBio sentences (+10, +5 dB SNR ≤ 60% correct)
  • Contralateral ear: ≤ 80% on CNC words or AzBio sentences (+10, +5 dB SNR ≤ 80% correct)
  • Low frequency Pure Tone Average (PTA- 125, 250, 500 Hz) ≤ 55 dB HL in the ear to be implanted.
  • Severe to profound mid to high-frequency sensorineural hearing loss (threshold average of 1000, 2000, 3000, and 4000 Hz ≥75 dB HL) in the ear to be implanted.
  • Low frequency PTA ≤ 55 dB HL sloping to moderately severe to profound mid-to high frequency sensorineural hearing loss (threshold average of 1000, 2000, 3000, 4000 Hz ≥ 60 dB) in the contralateral ear.
  • Proficient in English.
  • Undergoing implantation with a current generation CI device from either Cochlear Limited or Advanced Bionics AG.
  • Cochlear Limited devices include: Nucleus CI612, CI622, CI632, CI624
  • Advanced Bionics AG devices include: HiFocus SlimJ, Mid-Scala
  • Stated willingness and ability to complete testing and all associated study visits.
What rules you out
  • Previous cochlear implantation.
  • Prelingual onset of hearing loss.
  • Abnormal inner ear anatomy on CT imaging.
  • Auditory neuropathy spectrum disorder.
  • Retrocochlear pathology such as a vestibular schwannoma or stroke.
  • Unwillingness or inability to comply with all investigational requirements including the randomization process.
  • Additional medical, or social barriers that would prevent completion of all study requirements.
  • Medical condition contraindicated for surgery.
  • Device selection of Med El CI (per the patient's selection).

The study team makes the final eligibility decision.

Where it's taking place

  • Rochester, Minnesota, United States
  • St Louis, Missouri, United States
  • Chapel Hill, North Carolina, United States
  • Columbus, Ohio, United States
  • Milwaukee, Wisconsin, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years to 79 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Rochester, Minnesota, United States; St Louis, Missouri, United States; Chapel Hill, North Carolina, United States; Columbus, Ohio, United States; Milwaukee, Wisconsin, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.